Study Links GLP-1 Use to Lower Obesity-Related Cancer Risk Compared to Insulin | Retatrutide News

GLP-1 agonists were associated with a lower three-year risk of obesity-related cancer than insulin. The study does not prove GLP-1 drugs prevent cancer,...
Clinical Trials · November 5, 2026